Cortria Corporation Establishes Scientific Advisory Board to Guide Development of TRIA-662
Cortria Corporation today announced the formation of a Scientific Advisory Board (SAB) comprised of distinguished cardiologists, clinical researchers and globally-recognized experts in the field of dyslipidemia. Members of the Cortria Scientific Advisory Board include:
-Jean-Claude Tardif, M.D., Professor of Medicine and Director of the Research Center, Montreal Heart Institute (Chairman of Cortria Scientific Advisory Board)
-H. Bryan Brewer, M.D., Director of Lipoprotein and Atherosclerosis Research, MedStar Research Institute, Washington Hospital Center
-B. Gregory Brown, M.D., Ph.D., Professor of Medicine, Division of Cardiology, University of Washington Medical School
-Mark E. McGovern, M.D., former Executive Vice President, Medical Affairs and Chief Medical Officer, Kos Pharmaceuticals
-David D. Waters, M.D., Emeritus Professor, University of California, San Francisco, former Chief of Cardiology, San Francisco General Hospital and Distinguished Professor of Medicine, U.C.S.F.
The SAB will actively advise Cortria in designing the clinical development strategy for TRIA-662, currently in Phase 2 clinical development for dyslipidemia, an atherogenic disorder characterized by abnormal fat levels in the bloodstream. TRIA-662 contains a previously unexplored metabolite of niacin that has shown the potential to provide the lipid-controlling benefits of niacin without causing skin flushing. Skin flushing is a well-known side effect of niacin and severely limits use of currently available niacin-containing therapies.
“TRIA-662 has shown promise as an investigational agent for treating dyslipidemia and I am very pleased to see the establishment of a Scientific Advisory Board to guide its development,” commented Dr. Tardif, Professor of Medicine at the Montreal Heart Institute and Chairman of the Cortria Scientific Advisory Board. “TRIA-662 exhibited anti-dyslipidemic activities in initial patient studies and was generally well-tolerated, without evidence of the flushing side effect typical of niacin therapy. In preclinical models of disease, TRIA-662 also inhibited the formation of atherosclerotic plaque, prevented development of endothelial dysfunction and stimulated selective release of prostacyclin–all potentially desirable cardioprotective properties when translated to the clinical situation.”
“We are very honored to have such a distinguished group of physicians and clinical researchers join the Cortria Scientific Advisory Board,” commented Daniel Grau, Cortria CEO and Vice-Chairman. “Cortria’s ability to attract cardiovascular key opinion leaders to the SAB, and in parallel to attract pharmaceutical executives from major cardiovascular franchises to the management team and industry advisory group, testifies to the broad scientific, medical and commercial appeal of TRIA-662.”
TRIA-662 is currently in Phase 2 clinical development for the treatment of dyslipidemia, an atherogenic disorder characterized by abnormal fat levels in the bloodstream. In preliminary human studies, TRIA-662 demonstrated the potential to provide the lipid-controlling benefits of niacin therapy without causing skin flushing. Niacin was the first lipid-modifying agent proven in outcomes trials to extend life, yet the side-effects of niacin, principally skin flushing, cause many patients to discontinue therapy and substantially limit the drug’s potential. Previous efforts to create a flush-free niacin therapeutic – using extended release formulations, dose titration and, more recently, fixed dose combination technologies – have not been successful. As a result, TRIA-662 represents an important opportunity as a new first-line therapy in the multi-billion dollar cardiovascular risk reduction market.
Cortria is a clinical-stage pharmaceutical company focused on developing safe and well-tolerated medicines to fight cardiovascular disease. Cortria is based in Boston, MA and backed by Domain Associates and MVM Life Science Partners.
(c) 2008 Cortria Corporation. All rights reserved.